Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
PRESS RELEASE REGULATED INFORMATION 27 April 2022, 07:00 am CEST   Publication of Annual Report 2021 Ghent, Belgium – 27 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today invites the holders...
Read More
PRESS RELEASE REGULATED INFORMATION 12 April 2022, 07:00 CET   alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months vs. published literature Patient enrolment and implants completed; primary endpoint on track for Q4 2022 FDA regulatory submission planned for mid-2023 DSR® in heart failure...
Read More
PRESS RELEASE Regulated information 28 March 2022, 6 p.m. CET   Ghent, Belgium – 28 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today that it received a transparency notification from...
Read More
PRESS RELEASE Regulated information 18 March 2022, 6 p.m. CET   Ghent, Belgium – 18 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today that it received transparency notifications from the...
Read More
PRESS RELEASE REGULATED INFORMATION 10 March 2022, 18:00 CET   Ghent, Belgium, 10 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that in the context of the capital increase that was...
Read More
PRESS RELEASE REGULATED INFORMATION 21 January 2022, 06:00 pm CET   Ghent, Belgium – 21 January 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian...
Read More
PRESS RELEASE REGULATED INFORMATION 27 July 2021, 6:00 pm CEST   Ghent, Belgium, 27 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian Act...
Read More
PRESS RELEASE REGULATED INFORMATION 27 May 2021, 06:00 pm CEST   Ghent, BELGIUM – 27 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that all proposed resolutions submitted to the...
Read More
PRESS RELEASE REGULATED INFORMATION 3 May 2021, 07:00 am CEST   Ghent, Belgium, 3 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian Act...
Read More
PRESS RELEASE REGULATED INFORMATION 27 April 2021, 07:00 am CEST   Publication of Annual Report 2020 Ghent, Belgium, 27 April 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today invites the holders of...
Read More
1 3 4 5 6 7 8

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES